Report Detail
North America Hereditary Cancer Testing Market to 2027 - Regional Analysis and Forecasts by Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Country
- RnM3820304 |
- 08 November, 2019 |
- Global |
- 132 Pages |
- The Insight Partners |
- Biotechnology
The North America hereditary cancer testing market is expected to reach US$ 3,247.37 Mn in 2027 from US$ 1,255.79 Mn in 2018. This market is projected to grow at a growth rate of 11.6% from 2019-2027.
The growth of the hereditary cancer testing market is primarily attributed to increasing as increasing prevalence of hereditary cancer and growing awareness about hereditary cancer have been boosting the market over the years. On the other hand, favorable reimbursement scenario is expected to have a positive effect on the growth of the North America hereditary cancer testing market in the coming years.
Genetic testing helps evaluate the chance of developing cancer in a lifetime. The genetic testing is done by searching for specific mutations in genes, chromosomes, or proteins. An inherited gene mutation causes hereditary cancer. An inherited gene is the one which is passed from parent to child in a family. Various methods are used for hereditary cancer testing; it includes genetic counseling. The counseling provides a discussion regarding recommendations for preventive care and screening with the patient. They support groups and other information resources and provide emotional support to the person getting the results. The technological advances have allowed more significant integration of genomics into health care delivery, facilitating screening and molecular diagnostics along with the precise detection of microbes, and prescription and monitoring of efficiency of more accurate therapeutics. The growing demand for noninvasive method for cancer testing may stimulate market growth during the forecast period.
North America hereditary cancer testing market is segmented by diagnosis type, technology, and end user. On the basis of diagnosis type, the market is segmented into biopsy and imaging. On the basis of technology, the market is segmented into sequencing, PCR, and microarray. Based on end user, the market is segmented into diagnostic centers, hospital, and clinics. In 2018, the imaging held the largest share in the market, by diagnosis type.
Some of the major primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), Centers for Medicare & Medicaid Services (CMS), National Institute of Cancer Prevention and Research (NICPR), National Cancer Institute, Canadian Institutes of Health Research (CIHR) and others.
TABLE OF CONTENTS
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
2. North America Hereditary Cancer Testing Market - Key Takeaways
3. North America Hereditary Cancer Testing Market - Market Landscape
- 3.1 Overview
- 3.2 Market Segmentation
- 3.2.1 Global Hereditary Cancer Testing Market - By Diagnosis Type
- 3.2.2 Global Hereditary Cancer Testing Market - By Technology
- 3.2.3 Global Hereditary Cancer Testing Market - By End User
- 3.2.4 North America Hereditary Cancer Testing Market - By Country
- 3.3 PEST Analysis
4. North America Hereditary Cancer Testing Market - Key Market Dynamics
- 4.1 Key Market Drivers
- 4.1.1 Favourable Reimbursement Scenario
- 4.1.2 Growing Awareness About Hereditary Cancer
- 4.2 Key Market Restraints
- 4.2.1 Gender Gap In Cancer Genetic Test
- 4.3 Key Market Opportunities
- 4.3.1 Whole Genome Sequencing (WGS) for Cancer
- 4.4 Future Trends
- 4.4.1 Demand For Personalized Medicines
- 4.5 Impact Analysis
5. Hereditary Cancer Testing Market - North America Analysis
- 5.1 North America Hereditary Cancer Testing Market Revenue Forecasts And Analysis
- 5.2 Performance of Key Players
6. North America Hereditary Cancer Testing Market Analysis - By Diagnosis Type
- 6.1 Overview
- 6.2 North America Hereditary Cancer Testing Market by Diagnosis Type, 2018 & 2027 (%)
- 6.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Diagnosis Type (US$ Mn)
- 6.4 Biopsy Market
- 6.4.1 Overview
- 6.4.2 North America Biopsy Market Revenue and Forecasts to 2027 (US$ Mn)
- 6.4.3 Blood Sample Market
- 6.4.3.1 Overview
- 6.4.3.2 North America Blood Sample Market Revenue and Forecasts to 2027 (US$ Mn)
- 6.4.4 Cheek Swab Sample Market
- 6.4.4.1 Overview
- 6.4.4.2 North America Cheek Swab Sample Market Revenue and Forecasts to 2027 (US$ Mn)
- 6.5 Imaging Market
- 6.5.1 Overview
- 6.5.2 North America Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
7. North America Hereditary Cancer Testing Market Analysis - By Technology
- 7.1 Overview
- 7.2 North America Hereditary Cancer Testing Market by Technology, 2018 & 2027 (%)
- 7.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Technology (US$ Mn)
- 7.4 Sequencing Market
- 7.4.1 Overview
- 7.4.2 North America Sequencing Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.5 Polymerase Chain Reaction (PCR) Market
- 7.5.1 Overview
- 7.5.2 North America Polymerase Chain Reaction (PCR) Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.6 Microarray Market
- 7.6.1 Overview
- 7.6.2 North America Microarray Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Hereditary Cancer Testing Market Analysis - By End User
- 8.1 Overview
- 8.2 North America Hereditary Cancer Testing Market by End User, 2018 & 2027 (%)
- 8.3 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By End User (US$ Mn)
- 8.4 Diagnostic Centers Market
- 8.4.1 Overview
- 8.4.2 North America Diagnostic Centers Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.5 Hospitals Market
- 8.5.1 Overview
- 8.5.2 North America Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)
- 8.6 Clinics Market
- 8.6.1 Overview
- 8.6.2 North America Clinics Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027
- 9.1.1 Overview
- 9.1.2 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.3 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
- 9.1.3.1 North America Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
- 9.1.4 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 9.1.5 North America Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
- 9.1.6 North America Hereditary Cancer Testing Market Revenue and Forecasts to 2027, By Country (%)
- 9.1.7 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.7.1 US Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.7.2 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
- 9.1.7.2.1 US Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
- 9.1.7.3 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 9.1.7.4 US Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
- 9.1.8 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.8.1 Canada Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.8.2 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
- 9.1.8.2.1 Canada Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
- 9.1.8.3 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 9.1.8.4 Canada Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
- 9.1.9 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.9.1 Mexico Hereditary Cancer Testing Market Revenue and Forecasts to 2027 (US$ Mn)
- 9.1.9.2 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Diagnosis Type (US$ Mn)
- 9.1.9.2.1 Mexico Hereditary Cancer Testing Market Revenue And Forecasts To 2027, By Biopsy (US$ Mn)
- 9.1.9.3 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 9.1.9.4 Mexico Hereditary Cancer Testing Market Revenue And Forecasts to 2027, By End User (US$ Mn)
10. Hereditary Cancer Testing Market - Industry Landscape
- 10.1 Overview
- 10.2 Growth Strategies in the Hereditary Cancer Testing Market, 2016-2019
- 10.3 Organic Growth Strategies
- 10.3.1 Overview
- 10.3.2 Product Launch
- 10.3.3 Product Approval
- 10.3.4 Others
- 10.4 Inorganic Growth Strategies
- 10.4.1 Overview
- 10.4.2 Partnership
- 10.4.3 Agreement & Collaboration
- 10.4.4 Acquisition
11. Hereditary Cancer Testing Market-Key Company Profiles
- 11.1 Hologic Inc.
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Financial Overview
- 11.1.4 Product Portfolio
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 Koninklijke Philips N.V.
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Financial Overview
- 11.2.4 Product Portfolio
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 Quest Diagnostics Incorporated
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Financial Overview
- 11.3.4 Product Portfolio
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 Myriad Genetics, Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Overview
- 11.4.4 Product Portfolio
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Cancer Genetics Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Financial Overview
- 11.5.4 Product Portfolio
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Invitae Corporation
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Financial Overview
- 11.6.4 Product Portfolio
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Myogenes
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Financial Overview
- 11.7.4 Product Portfolio
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Strand Life Sciences Pvt. Ltd.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Financial Overview
- 11.8.4 Product Portfolio
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
- 11.9 Pathway Genomics Corporation
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Financial Overview
- 11.9.4 Product Portfolio
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
- 11.10 CENTOGENE AG
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Financial Overview
- 11.10.4 Product Portfolio
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
12. Appendix
- 12.1 About The Insight Partners
- 12.2 Glossary Of Terms
- 12.3 Methodology
- 12.3.1 Coverage
- 12.3.2 Secondary Research
Summary:
Get latest Market Research Reports on North America Hereditary Cancer Testing. Industry analysis & Market Report on North America Hereditary Cancer Testing is a syndicated market report, published as North America Hereditary Cancer Testing Market to 2027 - Regional Analysis and Forecasts by Diagnosis Type (Biopsy, Imaging); Technology (Sequencing, PCR, Microarray); End User (Hospital, Clinics, Diagnostic Centers), and Country. It is complete Research Study and Industry Analysis of North America Hereditary Cancer Testing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
